Symbols

PHVS

Pharvaris·NASDAQ

--(--)

PHVS Profile

Pharvaris N.V.

A clinical-stage company that develops novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks

Industry

Pharmaceutical

Established Date

09/30/2015

Listing Date

02/05/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

129

Fiscal Year Ends

12-31

Website

www.pharvaris.com

Security Type

Common stock

Office address

Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands

Business

Introduction

Pharvaris N.V. was incorporated in the Netherlands on September 30, 2015. The Company is a clinical-stage biopharmaceutical company focused on the development of deucrictibant, an oral small molecule bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema. Its R&D pipeline includes immediate-release capsules for on-demand treatment and sustained-release tablets for prevention, both of which have completed Phase 2 and Phase 3 trials.